Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in human and murine acute myeloid leukemia

Blood (2022) 139 (9): 1340–1358.

https://doi.org/10.1182/blood.2020010344

Published: 2022

Includes: Supplemental data

Journal Articles

Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia

Parvathi Ranganathan, Xueyan Yu, Ramasamy Santhanam, Jessica Hofstetter, Alison Walker, Katherine Walsh, Bhavana Bhatnagar, Rebecca Klisovic, Sumithira Vasu, Mitch A. Phelps, Steven Devine, Sharon Shacham, Michael Kauffman, Guido Marcucci, William Blum, Ramiro Garzon

Blood (2015) 125 (17): 2689–2692.

https://doi.org/10.1182/blood-2014-10-607648

Published: 2015

Includes: Supplemental data

Journal Articles

Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia

Blood (2013) 121 (1): 159–169.

https://doi.org/10.1182/blood-2012-05-428573

Published: 2013

Includes: Supplemental data

Journal Articles

Quantification of the Active Decitabine-Triphosphate (DAC-TP) Metabolite: A Novel Pharmacoanalytical Endpoint for Optimization of Hypomethylating Therapy in Acute Myeloid Leukemia (AML)

Hongyan Wang, Ping Chen, Ph.D., Jiang Wang, Ramasamy Santhanam, Ph.D, Josephine Aimiuwu, Vijayasaradhi UV, Zhongfa Liu, Sebastian Schwind, MD, Alice S. Mims, MD, Rebecca B Klisovic, MD, Alison Walker, MD, Michael R. Grever, MD, Miguel Villalona-Calero, MD, John C. Byrd, MD, Ramiro Garzon, MD, William Blum, MD, Kenneth K. Chan, Ph.D, Guido Marcucci, MD

Blood (2012) 120 (21): 3578.

https://doi.org/10.1182/blood.V120.21.3578.3578

Published: 2012

Journal Articles

Phase I Study of Decitabine and Rapamycin in Relapsed/Refractory Acute Myelogenous Leukemia

Jane L. Liesveld, MD, Kristen O'Dwyer, MD, Michael W. Becker, MD, Deborah Mulford, MD, Alison Walker, MD, Rui Chen, PhD, Jeremy Bechelli, MS, Karen Rosell, BS, Craig T. Jordan, PhD, Mohammad Minhajuddin, PhD, Gordon L. Phillips, II, MD

Blood (2012) 120 (21): 3549.

https://doi.org/10.1182/blood.V120.21.3549.3549

Published: 2012

Journal Articles

Phase I Study of the Combination of Azacitidine (AZA) with MEC (Mitoxantrone, Etoposide and Cytarabine) Salvage Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia (AML): Early Results

Rebecca B Klisovic, MD, Hongyan Wang, Alison Walker, MD, Katherine Walsh, MD, Sumithira Vasu, MBBS, Ramiro Garzon, MD, Steven M. Devine, MD, Jiang Wang, Celia Garr, RN, Adam Norris, John C. Byrd, MD, Michael R. Grever, MD, William Blum, MD, Kenneth K. Chan, Ph.D, Guido Marcucci, MD

Blood (2012) 120 (21): 3616.

https://doi.org/10.1182/blood.V120.21.3616.3616

Published: 2012

Journal Articles

Priming of Mir-181a in Acute Myeloid Leukemia (AML) to Increase Chemosensitivity: A Phase I Trial of Lenalidomide (LEN) Followed by Idarubicin and Cytarabine.

William Blum, MD, Rebecca B Klisovic, MD, Alison Walker, MD, Sebastian Schwind, MD, Yao Jiang, Jiang Wang, Mitch Phelps, PhD, Susan Geyer, PhD, Steven M. Devine, MD, Kathy Walsh, MD, Sumithira Vasu, MBBS, John P. Curfman, Larry Schaaf, PhD, Celia Garr, RN, Cheryl Kefauver, RN, John C. Byrd, MD, Michael R. Grever, MD, Ramiro Garzon, MD, Guido Marcucci, MD

Blood (2012) 120 (21): 2619.

https://doi.org/10.1182/blood.V120.21.2619.2619

Published: 2012

Journal Articles

Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia

Blood (2012) 120 (12): 2466–2474.

https://doi.org/10.1182/blood-2012-05-429175

Published: 2012

Includes: Supplemental data

Journal Articles

Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia

Parvathi Ranganathan, Xueyan Yu, Caroline Na, Ramasamy Santhanam, Sharon Shacham, Michael Kauffman, Alison Walker, Rebecca Klisovic, William Blum, Michael Caligiuri, Carlo M. Croce, Guido Marcucci, Ramiro Garzon

Blood (2012) 120 (9): 1765–1773.

https://doi.org/10.1182/blood-2012-04-423160

Published: 2012

Journal Articles

Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia

Blood (2012) 119 (25): 6025–6031.

https://doi.org/10.1182/blood-2012-03-413898

Published: 2012

Includes: Supplemental data

Journal Articles

Phase II Study of the Cyclin-Dependent Kinase (CDK) Inhibitor Dinaciclib (SCH 727965) In Patients with Advanced Acute Leukemias

Ivana Gojo, MD, Alison Walker, MD, Maureen Cooper, MD, Eric J Feldman, MD, Swaminathan Padmanabhan, MBBS, MS, Maria R Baer, MD, Jennifer Poon, PharmD, Karen Small, BSN, Da Zhang, MS, Mariola Sadowska, PhD, Rajat Bannerji, MD, PhD

Blood (2010) 116 (21): 3287.

https://doi.org/10.1182/blood.V116.21.3287.3287

Published: 2010

Journal Articles

Phase 1 Trial of Decitabine and Bortezomib in High Risk Acute Myeloid Leukemia (AML)

William Blum, MD, Rebecca B. Klisovic, MD, Ramiro Garzon, MD, Alison Walker, MD, Sebastian Schwind, MD, Shujun Liu, PhD, Larry Schaaf, PhD, Celia Garr, RN, Steven M. Devine, MD, Michael R. Grever, MD, John C. Byrd, MD, Guido Marcucci, MD

Blood (2010) 116 (21): 3293.

https://doi.org/10.1182/blood.V116.21.3293.3293

Published: 2010

Journal Articles

Phase I Study of Lenalidomide in Acute Leukemia: Remissions in Post-Allogeneic Relapse of Acute Myeloid Leukemia.

Jason C. Chandler, MD, Rebecca B. Klisovic, MD, Mitch A. Phelps, PhD, Alison Walker, MD, Ramiro Garzon, MD, Xiaoxia Yang, Larry Schaaf, PhD, Sebastian Schwind, MD, Heiko Becker, MD, Shujun Liu, PhD, Chris Hickey, Cheryl Kefauver, RN, Jon Mickle, CNP, Steven M Devine, MD, Michael R. Grever, MD, John C. Byrd, MD, Guido Marcucci, MD, William Blum, MD

Blood (2009) 114 (22): 841.

https://doi.org/10.1182/blood.V114.22.841.841

Published: 2009

Journal Articles

Quantification of Intracellular Decitabine-Triphosphate with A Novel, Highly Sensitive and Specific LC-MS/MS Assay in Acute Myeloid Leukemia Patients Treated with Low Dose Decitabine.

Ping Chen, Ph.D., William Blum, M.D., Josephine Aimiuwu, B.S., Vijayasarathi Upadhyayula, Ph.D., Zhongfa Liu, Ph.D., Shujun Liu, Ph.D., Jiuxia Pang, B.S., Alison Walker, M.D., Rebecca B. Klisovic, M.D., Ramiro Garzon, M.D., Michael R. Grever, M.D., Miguel Villalona-Calero, M.D., John C. Byrd, M.D., Kenneth K Chan, Ph.D., Guido Marcucci, M.D.

Blood (2009) 114 (22): 3782.

https://doi.org/10.1182/blood.V114.22.3782.3782

Published: 2009

Journal Articles

Epigenetic Targeting Via Transcriptional Inhibition of DNA Methyltransferase: a Phase I Study of Bortezomib in Combination with 5-Azacytidine in Adults with Relapsed or Refractory Acute Myeloid Leukemia (AML).

William Blum, MD, Rebecca B. Klisovic, MD, Alison Walker, MD, Ramiro Garzon, MD, Shujun Liu, PhD, Larry J. Schaaf, PhD, Kristina Humphries, Michael R. Grever, Steven M. Devine, MD, John C. Byrd, Guido Marcucci, MD,

Blood (2009) 114 (22): 2065.

https://doi.org/10.1182/blood.V114.22.2065.2065

Published: 2009

Journal Articles

The mTOR Inhibitor Rapamycin Demonstrates Activity Against AML in Combination with Imatinib Mesylate and with 5-Azacytidine.

Jane L. Liesveld, MD, Karen Rosell, BS, Chaohui Lu, BS, Deborah Mulford, MD, Alison Walker, MD

Blood (2007) 110 (11): 4318.

https://doi.org/10.1182/blood.V110.11.4318.4318

Published: 2007

Journal Articles

Phase I Study of Cladribine, Cytarabine (Ara-C), Granulocyte Colony Stimulating Factor (G-CSF) (CLAG Regimen) and Simultaneous Escalating Doses of Imatinib Mesylate (Gleevec) in Relapsed/Refractory AML.

Camille N. Abboud, MD, Alison Walker, MD, Rami S. Komrokji, MD, Jainulabdeen J. Ifthikharuddin, MD, Connie Sparks, BS,CRA, Kelly Likly, MSN, Patti Messina, BSN, Deborah Mulford, MD, Jonathan Friedberg, MD, Michael W. Becker, MD, Faith Young, MD, Steven H. Bernstein, MD, August J. Salvado, MD, Gordon L. Phillips, MD, Jane L. Liesveld, MD

Blood (2006) 108 (11): 1958.

https://doi.org/10.1182/blood.V108.11.1958.1958

Published: 2006

NARROW

PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in human and murine acute myeloid leukemia

Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia

Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia

Quantification of the Active Decitabine-Triphosphate (DAC-TP) Metabolite: A Novel Pharmacoanalytical Endpoint for Optimization of Hypomethylating Therapy in Acute Myeloid Leukemia (AML)

Phase I Study of Decitabine and Rapamycin in Relapsed/Refractory Acute Myelogenous Leukemia

Phase I Study of the Combination of Azacitidine (AZA) with MEC (Mitoxantrone, Etoposide and Cytarabine) Salvage Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia (AML): Early Results

Priming of Mir-181a in Acute Myeloid Leukemia (AML) to Increase Chemosensitivity: A Phase I Trial of Lenalidomide (LEN) Followed by Idarubicin and Cytarabine.

Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia

Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia

Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia

Phase II Study of the Cyclin-Dependent Kinase (CDK) Inhibitor Dinaciclib (SCH 727965) In Patients with Advanced Acute Leukemias

Phase 1 Trial of Decitabine and Bortezomib in High Risk Acute Myeloid Leukemia (AML)

Phase I Study of Lenalidomide in Acute Leukemia: Remissions in Post-Allogeneic Relapse of Acute Myeloid Leukemia.

Quantification of Intracellular Decitabine-Triphosphate with A Novel, Highly Sensitive and Specific LC-MS/MS Assay in Acute Myeloid Leukemia Patients Treated with Low Dose Decitabine.

Epigenetic Targeting Via Transcriptional Inhibition of DNA Methyltransferase: a Phase I Study of Bortezomib in Combination with 5-Azacytidine in Adults with Relapsed or Refractory Acute Myeloid Leukemia (AML).

The mTOR Inhibitor Rapamycin Demonstrates Activity Against AML in Combination with Imatinib Mesylate and with 5-Azacytidine.

Phase I Study of Cladribine, Cytarabine (Ara-C), Granulocyte Colony Stimulating Factor (G-CSF) (CLAG Regimen) and Simultaneous Escalating Doses of Imatinib Mesylate (Gleevec) in Relapsed/Refractory AML.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only